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Niclosamide is an anthelmintic drug that has mainly been 
used for over 50 years to mainly treat tapeworm infections. 
However, with the increase in drug repurposing initiatives, 
niclosamide has emerged as a true hit in many screens 
against various diseases. Indeed, from being an anthelmintic 
drug, it has now shown potential in treating Parkinson’s 
disease, diabetes, viral and microbial infections as well as 
various cancers. Such diverse pharmacological activities are 
a result of niclosamide’s ability to uncouple mitochondrial 
phosphorylation and modulate a selection of signaling 
pathways, such as Wnt/β-catenin, mTOR and JAK/STAT3, 
which are implicated in many diseases. In this highlight, we 
will discuss the plethora of diseases that niclosamide has 
shown promise in treating.  
Following its discovery in the early 1950s, niclosamide (Figure 1) 
was initially used as a molluscicide to kill snails[1] and around a 
decade later, it was found to be effective against human 
tapeworm infection.[2] Its use in humans to treat tapeworm 
infection started in 1982 following FDA-approval and has since 
been one of the drugs in the World Health Organization’s 
essential list of medicines. Structurally, niclosamide belongs to a 
large group of lipophilic, weakly-acidic molecules called 
salicylanilides (Figure 1).[3]  
Figure 1. Chemical structures of salicylanilides and niclosamide. 
 
Despite its wide use as an anthelmintic drug, the mechanism of 
action of niclosamide is yet to be completely understood. Early 
studies have linked niclosamide’s activity to the uncoupling of 
oxidative phosphorylation.[4] However, over the last decade or so, 
niclosamide has been shown to act on other targets such as 
Wnt/β-catenin, mTOR and JAK/STAT3 signaling pathways 
[reviewed by Chen et al[5]], which inevitably linked niclosamide’s 
therapeutic potential to many diseases that involve these 
important signaling cascades. The increasing interest over the 
last decade in niclosamide is reflected in the significant rise in the 
number of publications that studied this drug (Figure 2). Herein, 
we briefly discuss the numerous diseases niclosamide has shown 
promise in treating. 
 
 
 
Figure 2. The number of niclosamide papers published since 2010. The data 
was obtained from PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) using the 
search term ‘niclosamide’ and fixing the dates from 1st January to 31st December 
of each indicated year. 
 
Pharmacological activities of niclosamide 
1. Parkinson’s disease (PD) 
As mutations that impair the catalytic activity of the mitochondrial 
serine/threonine protein kinase PINK1 (PTEN-induced kinase 1) 
were found to cause early onset PD[6] through neuronal apoptosis, 
it became apparent that small molecules that activate PINK1 
would have neuroprotective effects and thus have the potential to 
treat PD.[7] Equipped with the fact that PINK1 is activated by 
mitochondrial depolarization, Barini et al.[8] investigated whether 
niclosamide[9], which is known to cause mitochondrial 
depolarization, could activate PINK1. The results showed that 
niclosamide was a potent activator of PINK1 in cells. The study 
showed that niclosamide was not a direct activator of PINK1 as 
no activation was observed when recombinant PINK1 was 
incubated with PINK1 in vitro. However, it was shown that 
niclosamide caused mitochondrial depolarization, a phenomenon 
that was reversible following the removal of niclosamide from the 
cell media.[8] Impressively, niclosamide was also shown to 
activate PINK1 in cultured neurons. Together, this study 
highlighted the PINK1-mediated neuroprotective promise 
niclosamide may hold. Further in vivo studies in PD disease 
models are needed to establish the ability of niclosamide to treat 
this disease.   
2. Type 2 Diabetes Miletus (T2DM) 
Niclosamide ethanolamine, the salt form of niclosamide, which 
exhibits improved aqueous solubility was shown to improve the 
symptoms of T2DM in mice.[10] Indeed, niclosamide treatment of 
mice fed on high fat diet led to improved metabolism, increased 
lipid oxidation and high energy expenditure.  Additionally, in db/db 
mice wherein diabetes is induced as a result of mutations causing 
deficiency in leptin receptor activity, niclosamide ethanolamine 
was shown to be effective in improving glycemic control, treating 
hyperglycemia and slowing down the progression of the disease. 
In a subsequent study, niclosamide piperazine, which is another 
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salt form of niclosamide, was also found to have comparable 
efficacy in treating T2DM.[11] It has been suggested that 
niclosamide’s anti-diabetes therapeutic potential is due to the 
inhibition of the glucagon signaling PKA pathway.[12]  
3. Bacterial infections 
Niclosamide has also shown antimicrobial activities against 
various bacterial infections such as Methicillin-resistant 
Staphylococcus aureus (MRSA)[13] [14], Tuberculosis (TB)[15], and 
Anthrax[16]. In a drug repurposing study using a library of FDA 
approved drugs, niclosamide was found to specifically inhibit the 
growth of the Gram-positive bacteria and to display a strong in 
vivo and in vitro activity against MRSA (MIC = 0.125 µg/ml).[13] 
Such finding showed that niclosamide was as effective as 
vancomycin, the current drug of choice for treating MRSA.[13] 
Subsequently, niclosamide was investigated for its potential as an 
antimicrobial surface coating against device associated and 
hospital acquired infections.[14] Highly versatile niclosamide-
based antimicrobial coatings were developed and these were 
shown to clear existing infections and prevent biofilm formation at 
very low concentrations.[14] 
Niclosamide was also shown to have significant anti-tuberculosis 
(TB) activity (MIC = 0.5-1 µg/ml).[15] Interestingly, niclosamide 
exerted pharmacological activity against stationary phase 
tubercle bacilli and multidrug resistant tuberculosis. However, it 
was noted that there was potential toxicity to mammalian cells 
when niclosamide was used at MIC and hence topical use of 
niclosamide against surface-located tuberculosis may hold better 
therapeutic promise. 
Furthermore, niclosamide was identified to be able to significantly 
protect cells from an anthrax lethal toxin as well as from lethal 
factor Pseudomonas exotoxin fusion protein and diphtheria toxin 
at low micromolar concentrations.[16]  This activity was linked to 
obstructing the process of anthrax toxin internalization and 
directly linked to endosome acidification.[16]  
4.  Viral infections 
Niclosamide has been suggested for the potential use as a broad-
spectrum antiviral to target host pathways used by viruses for 
infection unlike the current antiviral strategies which are directed 
against a specific viral target.[17] This broad antiviral activity of 
niclosamide has been linked to its ability to neutralize the 
endosomal pH and as a result disrupting the pH-dependent 
membrane fusion required for the virus entry.  
To date, several studies have indicated the potential use of 
niclosamide to treat Coronaviruses (SARS-CoV and chikungunya 
virus)[18], Zika[19] and Ebola viruses.[20]Niclosamide was 
discovered to be able to inhibit the coronavirus, SARS-CoV 
replication at a low micromolar concentrations. Viral antigen 
synthesis was totally abolished at niclosamide concentration as 
low as 1.56 µM.[18] The exact mode of action is not clear, but 
niclosamide was found not to interfere with the virion’s attachment 
and entry into cells as it was still active even when added 3 hours 
after viral infection of cells.  Some in silico studies suggested the 
potential binding of niclosamide to the SARS-CoV main 
proteinase.[19] However, only a modest activity of niclosamide 
against this proteinase was reported (IC50 = 40 µM).[20] Moreover, 
niclosamide exhibited antiviral activity against chikungunya virus 
(CHIKV) using CHIKV 26S mediated insect cell fusion screening 
assay and was able to inhibit virus entry and cell-to-cell 
transmission of CHIKV infection[20].  In light of the recent outbreak 
of Zika and Ebola infection diseases, there was focus on the drug 
repurposing screening of FDA approved drugs for the rapid 
identification of potential therapeutic agent to meet the urgent 
medical need to treat these infections. Using such approach, 
niclosamide was identified as an inhibitor of the Zika virus.[21] 
Further validation assays confirmed the ability of niclosamide to 
significantly reduce Zika RNA levels and suppress the production 
of infectious Zika particles at sub-micromolar concentrations.[21] 
Subsequently, niclosamide emerged as a positive hit from 
another drug repurposing screen aimed at identifying clinically 
used agents that may have activity against the Ebola virus (EC50 
= 1.5 µM).[22] 
5. Cancer 
By far, the disease that has received the most attention in the 
repurposing of niclosamide is cancer. To date, niclosamide has 
been shown to exhibit anticancer activity against colon,[23] 
breast,[24] prostate,[25] glioblastoma,[26] osteosarcoma,[27] 
ovarian,[28] leukemia,[29] adrenocortical carcinoma,[30] lung[31] and 
oral[32] cancers.[5] 
These observed anticancer activities have been linked to 
niclosamide’s ability to damage tumor cell mitochondria, induce 
apoptosis, inhibit tumor cell proliferation and inhibit various 
aberrant tumor signaling pathways including Wnt/β-catenin, 
mTORC1, STAT3, nuclear factor-κB (NF-κB) and Notch pathway 
(reviewed in detail by Moskaleva et al[33]). In addition to this broad 
spectrum anticancer activity, niclosamide was also shown to 
inhibit cancer stem cells,[34] which are considered an attractive 
and promising anticancer therapeutic target since accumulating 
evidence has established their crucial role in cancer initiation, 
progression, establishment, recurrence and drug resistance.[35]  
Beyond its use as a single agent, niclosamide has been studied 
in combination with conventional chemotherapeutic agents. For 
instance, combination of niclosamide with cisplatin led to the 
inhibition of cisplatin-resistant triple negative breast cancer[36] and 
exhibited synergistic effect in cisplatin-resistant lung cancer 
cells[37].  Enhanced sensitivity of chronic myeloid leukemia cells to 
dasatinib[38] and that of cervical cancer cells to paclitaxel[39] was 
also achieved when these drugs were used in combination with 
niclosamide. Synergistic effects with erlotinib in colon cancer[40], 
head and neck cancer[41] and in erlotinib-resistant non-small lung 
cancer cells[31] have also been described. While the combination 
of niclosamide with bicalutamide led to overcoming enzalutamide 
and bicalutamide-resistant prostate cancer,[42] the combination 
with abiraterone was found to be effective in treating advanced 
castration resistant prostate cancer[43]. Furthermore, the use of 
niclosamide in conjunction with radiotherapy resulted in 
significant radio-sensitizing effects in triple-negative breast 
cancer cells[44] and overcame radio-resistance in lung cancer [45]. 
 
Considerations for the use of niclosamide as a therapeutic 
Along with the interest in repurposing niclosamide for these 
various diseases, it must be noted that niclosamide’s ability to 
influence many signaling pathways may work to its disadvantage 
as it would lead to diverse side effects. Also, the favorable safety 
profile of niclosamide in treating humans with tapeworm infection 
could be due to the fact that the site of action in this case is the 
gut and hence the drug is not absorbed to modulate various 
signaling cascades and cause side effects. With the newly 
discovered diseases where niclosamide may hold a therapeutic 
effect, systemic delivery maybe required and hence the safety 
profile of niclosamide in this case is still largely unknown. Current 
and future in vivo studies on niclosamide will provide a clearer 
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picture of its efficacy and toxicity, which will determine the 
success of these repurposing initiatives. 
 
Conclusion 
Niclosamide has shown great promise in treating many diseases 
through the uncoupling of oxidative phosphorylation and the 
manipulation of various cell signaling cascades. With this comes 
some safety concerns may arise following its systemic exposure. 
Insights into these safety issues will be attained in the near future 
from the various ongoing niclosamide clinical investigations. 
 
Statement. As this is a short Highlight of niclosamide’s 
pharmacological activities, it was impossible to include all of the 
studies published on niclosamide in this area. The studies 
discussed in this work are just a representation of the myriad of 
niclosamide’s therapeutic activities. 
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Many recent drug repurposing studies have identified the anthelmintic drug niclosamide as a potential treatment of numerous diseases. 
Although the mechanism of action of niclosamide in many cases is not fully understood, its in vitro and in vivo therapeutic effects have 
resurrected this old drug and generated some excitement about its potential repurposing for various diseases that are currently difficult 
to treat. 
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